PTC THERAPEUTICS, INC. (PTCT): restructuring charge — PTC discontinues early gene therapy programs, CFO terminated, vatiquinone Phase 3 misses primary endpoint

PTC THERAPEUTICS, INC.

Discontinues preclinical/early gene therapy programs; workforce reduction of ~8%; expects 15% OPEX savings in 2023; severance costs ~$7M.
CFO Emily Hill terminated effective immediately; employment ends Aug 20, 2023; eligible for severance without cause.
Phase 3 MOVE-FA trial of vatiquinone in Friedreich ataxia misses primary endpoint (mFARS change, p=0.14). Subscales and completers analysis show signals.
Company to discuss potential registration path with regulators despite missing primary endpoint; vatiquinone well tolerated.

item 2.05 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Emily Hill

Chief Financial Officer

PTCT · PTC THERAPEUTICS, INC.

Effective: 2023-05-20
Filed: May 23, 2023, 7:59 PM ET

On May 20, 2023, the Company informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Emily Hill was terminated as Chief Financial Officer at PTC THERAPEUTICS, INC..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On May 20, 2023, the Company informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

PTC THERAPEUTICS, INC. announced a restructuring with charges of approximately $7.0 million affecting gene therapy platform; primarily affects employees in the United States (reduction in workforce of approximately 8%).

Type: restructuring
Charge: approximately $7.0 million
Affected area: gene therapy platform; primarily affects employees in the United States
Headcount: reduction in workforce of approximately 8%

Exact text from the filing

other benefits. The Company estimates that the employee severance and benefit costs along with required pre-termination associated payments and benefits will be approximately $7.0 million, substantially all of which are expected to be cash expenditures. T he estimate of costs that the Company expects to incur, and the timing thereof, are subject to a number of

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-063688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.